Assam CM Himanta Signs Deal for Proton Beam Therapy Centre
Synopsis
Key Takeaways
A cancer treatment technology that was once the exclusive preserve of patients wealthy enough to fly to Europe or the United States is now headed to the Northeast. Chief Minister Dr. Himanta Biswa Sarma addressed the media on Saturday, 31 October 2026, following the signing of a formal agreement between the Government of Assam and IBA Particle Therapy India Pvt. Ltd. to establish a Proton Beam Therapy Centre in the state.
What proton therapy means for cancer patients in the Northeast
Proton beam therapy is not conventional radiation. Unlike standard X-ray-based radiotherapy, proton beams can be calibrated to deposit their maximum energy precisely at the tumour site — and then stop — sparing the surrounding healthy tissue from collateral damage. That precision matters enormously for paediatric cancers and tumours near the brain, spine, or heart, where even small doses to adjacent structures can cause lasting harm.
For patients in Assam and the broader Northeast, the practical implication has been brutal: those who needed proton therapy had to travel to Mumbai, Chennai, or increasingly abroad, often at catastrophic personal expense. This agreement is a direct attempt to close that gap.
IBA Particle Therapy and Assam's oncology push
IBA Particle Therapy India Pvt. Ltd. is the Indian arm of Ion Beam Applications, a Belgian company that is among the world's leading manufacturers and operators of proton therapy systems. The partnership brings globally proven technology into a state that has been systematically expanding its specialised medical infrastructure since Dr. Himanta Biswa Sarma took office in May 2021.
Assam already operates cancer hospitals in and around Guwahati, but a proton therapy centre would represent a qualitative leap — moving the state from palliative and conventional oncology into precision radiation medicine. It places Assam alongside a small number of Indian states actively pursuing international technology tie-ups to build out next-generation cancer care.
The regulatory and construction road ahead
Agreement signings are milestones, not finish lines. Before a single patient can be treated, the project must clear a demanding sequence: civil works for the shielded vault that houses the cyclotron, equipment import and installation, and — critically — regulatory clearances from the Atomic Energy Regulatory Board (AERB), which governs all particle therapy facilities in India. That process has stretched timelines at other proposed centres across the country.
The exact location of the facility within Assam, the project cost, the funding model, and the operational start date have not been officially disclosed. Those details will define whether this agreement translates into open doors for patients in the near term or the longer arc.
If the centre clears its regulatory and construction hurdles on schedule, the Northeast will have something it has never had before — a reason for cancer patients to stay home.